Related Experiment Video
Updated: Mar 15, 2026

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
Masafumi Horie1,2, Akira Saito1,2, Mitsuhiro Ohshima3
1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abstract:
Small cell lung cancer (SCLC) is a highly aggressive and metastatic malignancy that shows rapid development of chemoresistance and a high rate of recurrence. Recent genome and transcriptome studies have provided the whole landscape of genomic alterations and gene expression changes in SCLC. In light of the inter-individual heterogeneity of SCLC, subtyping of SCLC might be helpful for prediction of therapeutic response and prognosis. Based on the transcriptome data of SCLC cell lines, we undertook transcriptional network-defined SCLC classification and identified a unique SCLC subgroup characterized by relatively high expression of Hippo pathway regulators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) (YAP/TAZ subgroup). The YAP/TAZ subgroup displayed adherent cell morphology, lower expression of achaete-scute complex homolog 1 (ASCL1) and neuroendocrine markers, and higher expression of laminin and integrin. YAP knockdown caused cell morphological alteration reminiscent of floating growth pattern in many SCLC cell lines, and microarray analyses revealed a subset of genes regulated by YAP, including Ajuba LIM protein (AJUBA). AJUBA also contributed to cell morphology regulation. Of clinical importance, SCLC cell lines of the YAP/TAZ subgroup showed unique patterns of drug sensitivity. Our findings shed light on a subtype of SCLC with YAP and TAZ expression, and delineate molecular networks underlying the heterogeneity of SCLC.
Insights
Small cell lung cancer (SCLC) subtypes exist. A novel YAP/TAZ subgroup shows distinct cell morphology, gene expression, and drug sensitivity, offering new therapeutic avenues for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Small cell lung cancer (SCLC) is aggressive, metastatic, and develops chemoresistance.
- Genomic and transcriptome studies reveal SCLC heterogeneity.
- Subtyping SCLC may improve therapeutic response prediction and prognosis.
Purpose of the Study:
- To classify SCLC based on transcriptional networks.
- To identify and characterize a novel SCLC subgroup.
- To investigate the role of YAP/TAZ in SCLC biology and drug sensitivity.
Main Methods:
- Transcriptome data analysis of SCLC cell lines.
- Transcriptional network-defined classification.
- YAP knockdown experiments and microarray analysis.
- Assessment of cell morphology and drug sensitivity.
Main Results:
- A distinct SCLC subgroup with high YAP/TAZ expression was identified.
- This YAP/TAZ subgroup exhibits specific cell morphology, gene expression profiles (lower ASCL1, higher laminin/integrin), and drug sensitivities.
- YAP knockdown induced morphological changes, and YAP regulates genes like AJUBA, which also impacts cell morphology.
Conclusions:
- A novel YAP/TAZ-expressing SCLC subtype has been identified.
- This subtype presents unique molecular characteristics and clinical implications for drug sensitivity.
- Understanding these molecular networks is crucial for addressing SCLC heterogeneity and improving treatment outcomes.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...